Editas Medicine amends severance plan, extending CEO benefits to 18 months post-change-of-control

Editas Medicine, Inc.

Amended plan extends change-in-control termination window to include 3 months prior to a change in control.
Non-change-in-control termination now includes term for Good Reason; requires termination >3 months prior to change.
CEO severance: base salary continuation extended to 18 months (was 12) and COBRA contributions also to 18 months.
Plan covers named executive officers and other designated employees under an unfunded welfare benefit plan.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.